Skip to main content
Premium Trial:

Request an Annual Quote

Saladax, Transmedic Partner to Distribute Oncology Dosing Assays in Singapore, Hong Kong

NEW YORK (GenomeWeb News) – Saladax on Friday said that it has reached a distribution deal with Transmedic covering Saladax's MyCare oncology therapeutic dose management assays in Singapore and Hong Kong.

The MyCare assays include My5-FU, MyPaclitaxel, and MyDocetaxel products, which guide physicians in maintaining an optimal therapeutic range during the period of treatment, the Bethlehem, Penn.-based firm said.

Saladax recently said that it will begin offering the My5-FU assay as part of the MyCare portfolio after it regained rights to the assay from Myriad Genetics.

"We are pleased to have the opportunity to expand the distribution of our MyCare portfolio through this agreement with Transmedic, an experienced and well-respected commercialization partner that has a solid track record of effectively distributing innovative specialty medical products throughout Southeast Asia," Mark Myslinksi, senior vice president and COO of Saladax, said in a statement.

Based in Singapore, Transmedic distributes a range of life science products and medical devices.

Financial and other terms of the deal were not disclosed.

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.